<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucl Recept Signal</journal-id><journal-id journal-id-type="iso-abbrev">Nucl Recept Signal</journal-id><journal-id journal-id-type="publisher-id">NRS</journal-id><journal-title-group><journal-title>Nuclear Receptor Signaling</journal-title></journal-title-group><issn pub-type="epub">1550-7629</issn><publisher><publisher-name>Nuclear Receptor Signaling Atlas</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4594550</article-id><article-id pub-id-type="pmid">26445566</article-id><article-id pub-id-type="publisher-id">nrs13004</article-id><article-id pub-id-type="doi">10.1621/nrs.13004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mechanisms of peroxisome proliferator activated receptor &#947; regulation by non-steroidal anti-inflammatory drugs</article-title><alt-title alt-title-type="left-running">Running Head: PPAR&#947; and NSAIDs</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Puhl</surname><given-names>Ana C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Milton</surname><given-names>Flora A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cvoro</surname><given-names>Aleksandra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sieglaff</surname><given-names>Douglas H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Campos</surname><given-names>J&#233;ssica C.L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bernardes</surname><given-names>Amanda</given-names></name></contrib><contrib contrib-type="author"><name><surname>Filgueira</surname><given-names>Carly S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lindemann</surname><given-names>Jan Lammel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Tuo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Neves</surname><given-names>Francisco A.R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Polikarpov</surname><given-names>Igor</given-names></name></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>Paul</given-names></name></contrib><aff id="aff1">Instituto de F&#237;sica de S&#227;o Carlos, Universidade de S&#227;o Paulo, Av. Trabalhador Saocarlense 400, S&#227;o Carlos, SP, 13560-970, Brazil (ACP, JCLC, AB, IP)</aff><aff id="aff2">Instituto de Ci&#234;ncias da Sa&#250;de, Laborat&#243;rio de Farmacologia Molecular, Universidade de Bras&#237;lia, Brazil (FM, FARN)</aff><aff id="aff3">Genomic Medicine Program, Houston Methodist Research Institute, Houston, Texas (FM, AC, DHS, CSF, JLL, TD, PW)</aff></contrib-group><author-notes><corresp id="cor1">Corresponding Authors: PW, <email xlink:href="PWebb@HoustonMethodist.org">PWebb@HoustonMethodist.org</email> and IP, <email xlink:href="ipolikarpov@ifsc.usp.br">ipolikarpov@ifsc.usp.br</email></corresp><fn id="afn1"><p>Author Contributions: Conceived Study, ACP, AC, FAR, PW, IP; Performed experiments, ACP, FM, AC, DHS, JCLC, AB, CSF, JLL; Designed experiments, ACP, AC, FAR, PW, IP; Provided advice for experimental design, DHS, TD; Wrote the paper, ACP, PW, IP; Edited the paper, AC; Final approval of manuscript, PW, IP</p></fn><fn id="afn2"><p>Public Dataset Accession Numbers: PPAR&#947; in complex with diclofenac: PDB 4XTA; PPAR&#947; in complex with indomethacin: PDB 4XUM; PPAR&#947; in complex with sulindac sulfide: PDB 4XUH; Expression profiling: GEO dataset GSE64075</p></fn></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>05</day><month>10</month><year>2015</year></pub-date><volume>13</volume><elocation-id>e004</elocation-id><history><date date-type="received"><day>09</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#169; 2015, Puhl et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Puhl et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Non-Commercial
Attribution License, which permits unrestricted non-commercial use distribution and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="nrs13004.pdf"/><abstract><p>Non-steroidal anti-inflammatory drugs (NSAIDs) display anti-inflammatory, antipyretic and analgesic properties by inhibiting cyclooxygenases and blocking prostaglandin production. Previous studies, however, suggested that some NSAIDs also modulate peroxisome proliferator activated receptors (PPARs), raising the possibility that such off target effects contribute to the spectrum of clinically relevant NSAID actions. In this study, we set out to understand how peroxisome proliferator activated receptor-&#947; (PPAR&#947;/PPARG) interacts with NSAIDs using X-ray crystallography and to relate ligand binding modes to effects on receptor activity. We find that several NSAIDs (sulindac sulfide, diclofenac, indomethacin and ibuprofen) bind PPAR&#947; and modulate PPAR&#947; activity at pharmacologically relevant concentrations. Diclofenac acts as a partial agonist and binds to the PPAR&#947; ligand binding pocket (LBP) in typical partial agonist mode, near the &#946;-sheets and helix 3. By contrast, two copies of indomethacin and sulindac sulfide bind the LBP and, in aggregate, these ligands engage in LBP contacts that resemble agonists. Accordingly, both compounds, and ibuprofen, act as strong partial agonists. Assessment of NSAID activities in PPAR&#947;-dependent 3T3-L1 cells reveals that NSAIDs display adipogenic activities and exclusively regulate PPAR&#947;-dependent target genes in a manner that is consistent with their observed binding modes. Further, PPAR&#947; knockdown eliminates indomethacin activities at selected endogenous genes, confirming receptor-dependence of observed effects. We propose that it is important to consider how individual NSAIDs interact with PPAR&#947; to understand their activities, and that it will be interesting to determine whether high dose NSAID therapies result in PPAR activation.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>non-steroidal anti-inflammatory drugs</kwd><kwd>peroxisome proliferator activated receptors</kwd><kwd>X-ray structure</kwd><kwd>gene expression</kwd><kwd>3T3-L1</kwd><kwd>partial agonist</kwd></kwd-group></article-meta><notes><def-list list-type="simple" list-content="abbreviations"><title>Abbreviations: </title><def-item><term>NSAIDs</term><def><p>non-steroidal anti-inflammatory drugs</p></def></def-item><def-item><term>PPARs</term><def><p>peroxisome proliferator activated receptors</p></def></def-item><def-item><term>PPAR&#947;</term><def><p>peroxisome proliferator activated receptor &#947;</p></def></def-item><def-item><term>LBD</term><def><p>ligand binding domain</p></def></def-item><def-item><term>LBP</term><def><p>ligand binding pocket</p></def></def-item><def-item><term>COX</term><def><p>cyclooxygenase</p></def></def-item><def-item><term>AA</term><def><p>arachidonic acid</p></def></def-item><def-item><term>PGs</term><def><p>prostaglandins</p></def></def-item><def-item><term>H</term><def><p>helix</p></def></def-item><def-item><term>TZDs</term><def><p>thiazolidinediones</p></def></def-item><def-item><term>DMSO</term><def><p>dimethyl sulfoxide</p></def></def-item><def-item><term>PPRE</term><def><p>PPAR response element</p></def></def-item></def-list></notes></front><body><sec sec-type="intro"><title>Introduction</title><p>Non-steroidal anti-inflammatory drugs (NSAIDs) possess anti-inflammatory, antipyretic and analgesic activity. Therapeutic actions are attributed to inhibition of cyclooxygenases (COX-1 and COX-2) [<xref rid="r49" ref-type="bibr">Smith et al., 1994</xref>], enzymes that catalyze the first steps in conversion of arachidonic acid (AA) to prostaglandins (PGs). NSAIDs attach to a helical motif that protects the COX active site [<xref rid="r41" ref-type="bibr">Pountos et al., 2011</xref>]; preventing passage of AA towards the active site and blocking AA to PG conversion [2-5]. While the COX enzymes constitute major NSAID targets [<xref rid="r49" ref-type="bibr">Smith et al., 1994</xref>], they may not be the only pharmacologically relevant site of action [<xref rid="r5" ref-type="bibr">Brune et al., 1991</xref>; <xref rid="r18" ref-type="bibr">Gilroy and Colville-Nash, 2000a</xref>; <xref rid="r34" ref-type="bibr">Mukherjee et al., 1996</xref>]; there are also suggestions that some NSAID effects are mediated by peroxisome proliferator-activated receptors (PPARs) [<xref rid="r19" ref-type="bibr">Gilroy and Colville-Nash, 2000b</xref>; <xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>; <xref rid="r26" ref-type="bibr">Lehmann et al., 1997a</xref>; <xref rid="r60" ref-type="bibr">Wick et al., 2002</xref>], which are ligand-activated transcription factors that belong to the nuclear receptor family [<xref rid="r3" ref-type="bibr">Berger and Moller, 2002</xref>; <xref rid="r48" ref-type="bibr">Schoonjans et al., 1997</xref>]. Higher NSAID concentrations are needed for inhibition of COX-2 than for COX-1 [<xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>]. Given that these concentrations may approach levels required for PPAR activation <italic>in vitro</italic>, it is conceivable that high doses of certain NSAIDs could modulate PPARs [<xref rid="r18" ref-type="bibr">Gilroy and Colville-Nash, 2000a</xref>; <xref rid="r27" ref-type="bibr">Lehmann et al., 1997b</xref>].</p><p>There are three PPAR subtypes (&#945;, &#946; and &#947;) that each bind to a variety of synthetic and natural ligands, sometimes in greater than 1:1 stoichiometry [<xref rid="r17" ref-type="bibr">Forman et al., 1996</xref>; <xref rid="r24" ref-type="bibr">Kliewer et al., 1994</xref>]. PPAR&#947; is expressed mainly in adipose tissue, macrophages and inflammatory cells [<xref rid="r4" ref-type="bibr">Braissant et al., 1996</xref>; <xref rid="r44" ref-type="bibr">Ricote et al., 1998a</xref>; <xref rid="r56" ref-type="bibr">Tontonoz et al., 1994a</xref>; <xref rid="r57" ref-type="bibr">Tontonoz et al., 1994b</xref>] and mediates anti-inflammatory, adipogenic and insulin sensitizing effects of a well-known anti-diabetic drug class, thiazolidinediones (TZDs) [<xref rid="r22" ref-type="bibr">Jiang et al., 1998</xref>; <xref rid="r28" ref-type="bibr">Lehrke and Lazar, 2005</xref>; <xref rid="r45" ref-type="bibr">Ricote et al., 1998b</xref>; <xref rid="r46" ref-type="bibr">Ricote et al., 2000</xref>]. PPAR&#945; ligands also act through their cognate receptor to inhibit pro-inflammatory effects and reduce production of inflammatory interleukin-6 and PGs in smooth muscle cells, possibly reducing the risk for atherosclerosis [<xref rid="r30" ref-type="bibr">Li and Yang, 2011</xref>; <xref rid="r52" ref-type="bibr">Staels et al., 1998</xref>].</p><p>Precise position of PPAR&#947; ligands in the ligand binding pocket (LBP) influences receptor transcriptional outputs by modulation of activation function 2 (AF-2), a coactivator binding surface comprised of residues from C-terminal helix (H) 12, H3 and H5. Full PPAR&#947; agonists, such as TZDs, occupy two sub-pockets of the Y-shaped buried ligand binding pocket (LBP) in the PPAR ligand binding domain (LBD) [<xref rid="r37" ref-type="bibr">Nolte et al., 1998</xref>]. Here, the thiazolidine group of the ligand forms strong contacts with a tyrosine residue (Tyr473) on the inner surface of H12, thereby docking H12 into a rigid active position and promoting AF-2 activity. By contrast, H12 appears more mobile in the presence of partial agonists and the degree of H12 mobility inversely correlates with magnitude of AF-2 activity and agonist response. Partial agonists often occupy locations in the LBP that are close to H3 and the &#946;-sheet region [<xref rid="r6" ref-type="bibr">Bruning et al., 2007</xref>]. Such compounds partly stabilize H12 indirectly via effects upon H3, which forms part of the H12 docking site. Solution nuclear magnetic resonance studies has also revealed that some partial agonists fluctuate between binding modes and that this phenomenon is associated with slow equilibrium between different receptor conformations and incomplete H12 stabilization [27,28]. Finally, we showed that a very weak partial agonist/antagonist, the natural product luteolin, binds preferentially to a crystallographic PPAR&#947; conformer with H12 in an inactive position [<xref rid="r42" ref-type="bibr">Puhl et al., 2012</xref>]. Accordingly, PPAR&#947; ligands display a continuum of graded agonist/partial agonist responses that are linked to binding position and capacity to stabilize H12.</p><p>While some NSAIDs bind PPARs at high doses [<xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>; <xref rid="r26" ref-type="bibr">Lehmann et al., 1997a</xref>; <xref rid="r60" ref-type="bibr">Wick et al., 2002</xref>], the nature of PPAR/NSAID interactions and consequences for gene expression are poorly understood. In this study, we used X-ray crystallography to define how NSAIDs interact with the PPAR&#947; LBP and to relate these binding events to effects of these compounds on PPAR&#947; activity. We find that different NSAIDs display different PPAR&#947; binding modes with features that resemble agonists or partial agonists. NSAID-dependent changes in gene expression correlate well with predictions about varying degrees of PPAR&#947; partial agonism deduced from their binding modes. We propose that it is important to consider how individual NSAIDs interact with PPAR&#947; to fully understand their pharmacologic activities.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Reagents</title><p>NSAIDs ibuprofen, sodium diclofenac, indomethacin (Cayman Chemical); sulindac sulfide and rosiglitazone (Sigma Aldrich); PolarScreen&#8482; PPAR&#947; Competitor Assay, Green (Life Technologies); EnVision&#174; Multilabel Reader (Perkin Elmer); Mouse whole genome expression arrays (Illumina BeadChip Array MouseWG-6v2).</p></sec><sec><title>Fluorescence polarization assay</title><p>Competition data was generated in a 384-well Optiplate (Perkin Elmer, Cat. No. 6007270). Initial serial dilutions of the ligands were made in DMSO and added to the sample buffer. The assay plate was protected from light and incubated at room temperature for two hours before measurement. Fluorescence polarization was measured in the EnVision&#174; Multilabel Reader. Curve fitting was performed using Prism software from GraphPad Software, Inc. Error bars represent one standard deviation from the mean of triplicate reaction wells.</p></sec><sec><title>Transactivation assays</title><p>Cellular transactivation assays were performed in HeLa cells as described [<xref rid="r42" ref-type="bibr">Puhl et al., 2012</xref>]. We used 100 ng of plasmid PPRE-LUC (<italic>Firefly</italic> luciferase reporter vector), 10 ng of a CMV-driven PPAR&#947; expression vector (Promega), and 2.5 ng of pRL-TK, which contains <italic>Renilla</italic> luciferase (<italic>Dual-Luciferase Report Assay system</italic> Promega, Madison, WI). NSAIDs (&#177;) were tested for PPAR&#947; activation. EC<sub>50</sub> value was calculated from plots of the relationship between luminescence and ligand concentrations (10<sup>-9</sup> to 10<sup>-3</sup> M).</p></sec><sec><title>Protein expression and purification</title><p>The plasmid pET28a(+) (Novagen) encoding a human PPAR&#947; LBD, fused in frame to the C-terminus of a polyhistidine (His) tag was used for expression of PPAR&#947; in <italic>Escherichia coli</italic> strain BL21 (DE3). The expression and purification was conducted as described previously [<xref rid="r42" ref-type="bibr">Puhl et al., 2012</xref>].</p></sec><sec><title>Crystallization, data collection and structure determination</title><p>PPAR&#947; LBD at 10-15 mg/mL was mixed with 2 mM ligands on ice and allowed to stand at 4&#176;C overnight. The crystallization screens were performed under conditions similar to those described previously [<xref rid="r37" ref-type="bibr">Nolte et al., 1998</xref>] and also with several crystallization kits by sitting drop method using the robot <italic>Mosquito</italic> (TTP LABTech) and 0.5 &#181;l of protein complex solution mixed with 0.5 &#181;l precipitant solution and equilibrated against a 100 mL reservoir solution. Suitable crystals of PPAR&#947; in complex with sodium diclofenac were obtained in the condition containing 1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl<sub>2,</sub> whereas crystals in complex with indomethacin were grown in 0.95 M sodium citrate and 0.1 M HEPES pH 8.0. Crystals of PPAR&#947; in complex with sulindac sulfide were grown in 25% (w/v) PEG 6000 and 0.1 M Tris-HCl pH 8.5. Prior to data collection, crystals were soaked in a cryoprotectant containing the same reservoir solution complemented with 15% (v/v) ethylene glycol and rapidly cooled in a gaseous nitrogen stream at 100 K. X-ray diffraction data were collected in the protein crystallography MX2 beamline at the Laborat&#243;rio Nacional de Luz S&#237;ncrotron (LNLS, Campinas, Brazil) [<xref rid="r20" ref-type="bibr">Guimar&#227;es et al., 2009</xref>] and 5.0.1 beamline of Advanced Light Source (ALS) - Lawrence Berkeley National Laboratory (Berkeley, CA, EUA). Diffraction data were processed using MOSLFM [<xref rid="r29" ref-type="bibr">Leslie, 1999</xref>] and scaled with SCALA from the CCP4 program suite [<xref rid="r11" ref-type="bibr">Collaborative Computational Project, 1994</xref>]. The structures were determined by molecular replacement using the program PHASER from CCP4 Packages and the PPAR&#947; LBD (PDB code: 3SZ1[<xref rid="r42" ref-type="bibr">Puhl et al., 2012</xref>]) structure as a model. The programs PHENIX and COOT were used to alternately run cycles of refinement and model building [<xref rid="r1" ref-type="bibr">Adams et al., 2010</xref>; <xref rid="r15" ref-type="bibr">Emsley and Cowtan, 2004</xref>].</p></sec><sec><title>Adipocyte differentiation</title><p>3T3-L1 preadipocytes were cultured as previously described [29]. Two days post-confluency, cells were induced to differentiate using DMEM/F12 medium supplemented with 167 nM insulin, 1 &#956;M dexamethasone and 0.5 mM IBMX with or without Rosiglitazone or NSAIDs for three days [<xref rid="r23" ref-type="bibr">Klemm et al., 2001</xref>]. Cells were then maintained in Zen Bio AM-1-L1 medium (Zen-Bio, Inc., Research Triangle Park, NC). On day 8, lipid accumulation in the adipocytes was assessed using Oil Red O staining method as per manufacturer protocol [<xref rid="r23" ref-type="bibr">Klemm et al., 2001</xref>]. Test ligands were: control (DMSO); 1 &#956;M rosiglitazone; 10 &#956;M indomethacin; 75 &#956;M ibuprofen; 25 &#956;M sodium diclofenac. For image quantification, 4 random field 10x images of the 3T3-L1 cells were taken using a conventional light microscope and camera and exported to ImageJ software (NIH) and converted to grayscale. Posterior segmentation (isolation) was performed to obtain the red-stained area using thresholding and measured. Posterior adjustment to number of cells per image was obtained by multiplying % of stained area by count in a Neubauer chamber-like grid, calculated with statistical analysis and graphed with Graph Pad Prism.</p></sec><sec><title>Microarray analysis</title><p>3T3-L1 adipocytes were maintained and differentiated in the absence of Rosiglitazone and NSAIDs. On day 8, cells were treated with either vehicle 1 &#956;M Rosiglitazone, 25 &#956;M sodium diclofenac, 25 &#956;M sodium diclofenac or 75 &#956;M ibuprofen for 24hrs. Total RNA was extracted using Aurum Total RNA Fatty and Fibrous kit (BioRad). cRNA synthesis and labeling were performed using Illumina&#174; TotalPrep&#8482;-96 RNA Amplification Kit (Ambion). Biotin labeling <italic>in vitro</italic> transcription reaction was performed at 37&#176;C for 14 h. Biotinylated cRNA samples were hybridized to MouseWG-6v2 arrays at 58&#176;C for 18 h according to manufacturer's protocol, and scanned with an iScan reader. Raw data was obtained from GenomeStudio and subsequently background-subtracted and quantile-normalized using the lumi package [<xref rid="r14" ref-type="bibr">Du et al., 2008</xref>] and analyzed with the limma package [<xref rid="r50" ref-type="bibr">Smyth, 2004</xref>] within R [<xref rid="r54" ref-type="bibr">Team, 2011</xref>]. All analysis was corrected for multiple hypothesis testing [<xref rid="r2" ref-type="bibr">Benjamini and Hochberg, 1995</xref>], and effects determined to be significant with a &#8805;2-fold change an adjusted p-value &#8804;0.05 when compared to the vehicle (DMSO) control. To facilitate comparisons among the various treatments, all data were uploaded into a SQLite3 database (<ext-link ext-link-type="uri" xlink:href="http://www.sqlite.org/">http://www.sqlite.org/</ext-link>). Data are publicly deposited as GEO dataset GSE64075.</p></sec><sec><title>RT-qPCR</title><p>One &#956;g of isolated total RNA was reverse transcribed using the iScript cDNA Synthesis kit (Bio-Rad) according to the manufacturer&#8217;s recommendations. Quantitative PCR (RT-qPCR) was performed using Roche LightCycler 480 II Instrument with SYBR Green Mastermix (Roche). Primers were designed to span exon-exon boundaries to eliminate amplification of genomic DNA (primer sequences are listed in <xref ref-type="table" rid="t1">Table 1</xref>). Normalized Cp values (Critical point; Cp<sub>Target</sub> - Cp<sub>18S</sub>) of at least 3 biological replicates were analyzed by ANOVA followed by t-tests of DMSO (vehicle) vs. treatment, with treatment effect determined to be significant with a Bonferroni Corrected p-value &#8804; 0.05 (GraphPad Software, version 5.01; GraphPad).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Primer Sequences used for RT-qPCR.</title></caption></table-wrap></sec></sec><sec sec-type="results"><title>Results</title><sec><title>PPAR&#947; agonist and partial agonist activities of NSAIDs</title><p>We performed ligand binding and cellular transactivation assays to evaluate the NSAIDs as PPAR&#947; ligands. We first determined relative affinity of each compound for the PPAR&#947; LBD in a fluorescence polarization ligand displacement assay with the labeled PPAR&#947; ligand, Fluormone&#8482; PPAR&#947; Green (<xref ref-type="fig" rid="f1">Figure 1A</xref>). All four NSAIDs competed with the bound PPAR&#947; ligand. IC<sub>50</sub> values of 1.87 &#956;M, 3.70 &#956;M, 21.3 &#956;M, and 80.6 &#956;M were obtained for sulindac sulfide, sodium diclofenac, indomethacin, and ibuprofen, respectively.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><title>NSAIDs bind PPAR&#947; and modulate PPAR&#947; activity.</title><p>(A) Results of displacement assay using fluorescently labeled ligand. Y-axis represents fluorescence polarization units, X-axis represents concentration of the PPAR&#947; competitor ligands rosiglitazone, sulindac, diclofenac, indomethacin, and ibuprofen. Error bars represent one standard deviation from the mean of triplicate reaction wells. (B) Results of HeLa cell transactivation assays. Transfections used a PPAR&#947; expression vector and a PPAR response element driven luciferase promoter. Cells were treated with varying concentrations (10<sup>-9</sup> to 10<sup>-3</sup> M) of rosiglitazone, sodium diclofenac, indomethacin and ibuprofen. Assays were performed in three replicates and normalized for differences in efficiency by measuring internal control Renilla luciferase activity in the same lysate. Error bars represent standard deviation.</p></caption><graphic xlink:href="nrs-13-004-g1"/></fig><p>To assess NSAID activities, HeLa cells were transfected with PPAR&#947; and a PPAR responsive luciferase reporter and exposed to ligands. Rosiglitazone activated PPAR&#947; with EC<sub>50</sub> &lt;100 nM (<xref ref-type="fig" rid="f1">Figure 1B</xref>). Sodium diclofenac only elicited modest PPAR&#947; activation, reaching about 15% of the levels of activation obtained with rosiglitazone at maximal doses (<xref ref-type="fig" rid="f1">Figure 1B</xref>). However, diclofenac displayed high potency, with an EC<sub>50</sub> value just over 1 &#181;M. By contrast, indomethacin and ibuprofen activated PPAR&#947; efficiently, but with low potency. Both ligands reached near-maximal activation at the highest doses used, with indomethacin yielding close to 100% of the activity of rosiglitazone and ibuprofen around 50%. Assuming maximal responses at highest doses used, EC<sub>50</sub> values were 21 &#181;M and 56.8 &#181;M, respectively. Sulindac sulfide also elicited PPAR&#947; activation which approached 50-100% of that obtained with rosiglitazone in the 3-100 &#181;M concentration range (not shown). This ligand, however, also appeared toxic, as judged by inhibitory influences on renilla luciferase control and changes in cell appearance (not shown), making it difficult to assess true levels of agonism/partial agonism.</p><p>We conclude that assessments of rank order of ligand potency (<xref ref-type="fig" rid="f1">Figure 1B</xref>) agree with deduced affinities (<xref ref-type="fig" rid="f1">Figure 1A</xref>). Further, overall NSAID behavior is consistent with the idea that PPAR&#947; ligands display graded agonist/partial agonist responses, with diclofenac weakest, ibuprofen intermediate and indomethacin strongest. Sulindac sulfide may also fit into the latter category. Throughout the remainder of the paper, we refer to diclofenac as a weak partial agonist (&lt;20% of activity of full agonists such as TZDs) and other NSAIDs as strong partial agonists (&gt;50% of TZD activity).</p></sec><sec><title>NSAIDs exhibit diverse PPAR&#947; binding modes</title><p>To understand how NSAIDs bind to PPAR&#947;, we performed crystallization trials with bacterially expressed PPAR&#947; LBD and sodium diclofenac, indomethacin, sulindac sulfide and ibuprofen. We were not able to obtain crystals of PPAR&#947; with ibuprofen. However, three-dimensional co-crystal structures of the PPAR&#947; LBD with diclofenac, indomethacin and sulindac sulfide were solved in the monoclinic C2 space group and showed good geometric and crystallographic parameters, summarized in <xref ref-type="table" rid="t2">Table 2</xref>. The asymmetric unit contains a homodimer of the PPAR&#947; LBD, with one monomer (Chain A) in an active form and the other (Chain B) in an inactive conformation with C-terminal helix 12 (H12) displaced, probably as a consequence of crystallographic contacts reported earlier [<xref rid="r37" ref-type="bibr">Nolte et al., 1998</xref>]. Structures are shown in <xref ref-type="fig" rid="f2">Figure 2A-C</xref> and chemical structures and binding modes of the three NSAIDs are compared in <xref ref-type="fig" rid="f3">Figure 3</xref>. During the course of our study, Waku and co-workers described PPAR&#947; structures with several indole derivatives [<xref rid="r59" ref-type="bibr">Waku et al., 2010</xref>], including indomethacin (PDB: 3ADS). The ligand binding mode is essentially identical to our structure described below, but we have included our own structure because ligand position comparisons were performed with our own datasets.</p><p>The diclofenac binding mode most resembles that of PPAR&#947; partial agonists. The ligand binds both to Chain A and Chain B at a location between H3 and the &#946;-sheets, a common site of PPAR&#947; partial agonist interaction which we term site 2 [<xref rid="r37" ref-type="bibr">Nolte et al., 1998</xref>]. While there is significant overlap in ligand:amino acid contacts, diclofenac adopts different binding modes in each subunit (<xref ref-type="fig" rid="f2">Figure 2A</xref>). In both chains, diclofenac engages in hydrophobic contacts with residues L340, L333, L330, M364, C285, I281, I341 and R288. In Chain A, however, the dichloroanilino ring binds at the upper part of the pocket, towards helix H5, making hydrophobic contacts with E295, A292, S289 (H3) and M329 (H5), while in Chain B, the dichloroanilino ring binds in the opposite orientation, along H3 and the &#946;-sheet making hydrophobic interactions with I281 (H3) and M364 (H7) (<xref ref-type="fig" rid="f2">Figure 2A</xref>). Within Chain B, the diclofenac carboxyl group also makes strong hydrogen bond contacts with the side chain of S342, located in the &#946;-sheet (<xref ref-type="fig" rid="f2">Figure 2A</xref>). Interestingly, the Chain B diclofenac exhibits better defined electron density, suggesting that this may be the preferential binding mode. The PPAR&#947;/diclofenac structure also displayed the highest averaged B-factor value (89.32 &#197;) of the complexes reported here (<xref ref-type="table" rid="t2">Table 2</xref>) and disordered regions where model building proved unsuccessful. Therefore, the PPAR&#947;-diclofenac complex appears relatively dynamic.</p><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Structures of PPAR&#947; in complex with NSAIDs.</title><p>(A) PPAR&#947;/diclofenac structure. Left panel shows overall helical organization of PPAR&#947; Chain B (pale blue) with major structural features labeled, H12 (dark blue) in the inactive position and diclofenac in pink. The right panel represents a close up view of diclofenac (pink stick ball) with LBP amino acids. Interactions are mainly hydrophobic, and the amino acids shown as dots represent Van der Waals radii. (B) PPAR&#947;/Indomethacin structure. The right panel shows ligand-receptor interactions in Chain A, and the left panel shows the same in Chain B. Two molecules of indomethacin (blue stick ball) are present in Chain A and on one in Chain B. (C) PPAR&#947;/sulindac sulfide interactions represented as in <xref ref-type="fig" rid="f2">Figure 2B</xref>. Two molecules of sulindac sulfide are present in Chain A (green stick ball) and B (blue stick ball). A &#963;-weighted 2 <italic>Fo</italic> - <italic>Fc</italic> omit electron-density map is shown contoured at 1.0 &#963; for the area surrounding all ligands. Hydrogen bond distances are marked in all figures by dotted lines and red figures denoting angstroms (&#197;).</p></caption><graphic xlink:href="nrs-13-004-g2"/></fig><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Data collection and structure refinement statistics.</title></caption><table-wrap-foot><p><italic><sup>a</sup></italic> values in parameters refer to the last resolution shell</p><p><italic><sup>b</sup> R<sub>sym</sub></italic>: <italic>&#8721;<sub>hkl</sub>,<sub>j</sub></italic> (|I<sub>hkl</sub> - &lt;I<sub>hkl</sub>&gt;|)/<italic>&#8721;<sub>hkl</sub>,<sub>j</sub></italic> I<sub>hkl</sub>, where &lt;I<sub>hkl</sub>&gt; is the average intensity for a set of <italic>j</italic> symmetry-related reflections, and I<sub>hkl</sub> is the value of the intensity for a single reflection within a set of symmetry-related reflections.</p><p><italic><sup>c</sup>R<sub>factor</sub>: &#8721;<sub>hkl</sub></italic> (<italic>||F<sub>o</sub>| - |F<sub>c</sub>||</italic>)<italic>/&#8721;<sub>hkl</sub> |F<sub>o</sub>|,</italic> where <italic>F<sub>o</sub></italic> is the observed structure factor amplitude, and <italic>F<sub>c</sub></italic> is the calculated structure factor amplitude.</p><p><italic><sup>d</sup> R<sub>free</sub>: &#8721;<sub>hkl</sub>,T(||F<sub>o</sub>| - |F<sub>c</sub>||)/&#8721;<sub>hkl</sub> |F<sub>o</sub></italic>|, where a test set, <italic>T</italic> (5% of data), is omitted from the refinement.</p></table-wrap-foot></table-wrap><p>Indomethacin and sulindac sulfide adopt binding modes that share features with stronger PPAR&#947; agonists. Both ligands bind to the PPAR&#947; A chain in 2:1 stoichiometry (<xref ref-type="fig" rid="f2">Figure 2B, C</xref>). One ligand binds with its head group adjacent to H12 (site 1) and engages in hydrogen bonds with Tyr473 (H12), Ser289 (H3), His323 (H6) and His449 (H11) and extensive hydrophobic contacts with nearby LBP residues (<xref ref-type="fig" rid="f2">Figure 2B</xref>, <xref ref-type="fig" rid="f2">2C</xref> and <xref ref-type="fig" rid="f3">Figure 3B</xref>). The second Chain A ligand is located at site 2 [<xref rid="r6" ref-type="bibr">Bruning et al., 2007</xref>], between helix 3 and the &#946;-sheet. Both ligands form hydrophobic contacts with site 2 amino acids and the indomethacin carboxylic acid hydrogen bonds with the Ser342 main chain. Indomethacin and sulindac sulfide also bound to Chain B (<xref ref-type="fig" rid="f2">Figure 2B</xref>, <xref ref-type="fig" rid="f2">2C</xref> and <xref ref-type="fig" rid="f3">Figure 3B</xref>). One indomethacin ligand is present at site 2, where it displays a similar orientation to that seen in Chain A, between the &#946;-sheet and H3 (<xref ref-type="fig" rid="f2">Figure 2B</xref>). There are two sulindac sulfide ligand copies in Chain B. The first binds site 2, but in a different orientation from the equivalent ligand in Chain A site 2 (<xref ref-type="fig" rid="f2">Figure 2C</xref> and <xref ref-type="fig" rid="f3">Figure 3B</xref>). The second occupies site 1, but displays different LBP interactions from its Chain A counterpart because the displaced inactive position of H12 renders this helix unavailable for ligand contact. Here, sulindac sulfide forms hydrogen bonds with H323 and H449 onnly. Together, our data suggest that indomethacin and sulindac sulfide bind the PPAR&#947; active conformer in a mode that allows direct interactions with the inner surface of H12 at site 1, as well as recapitulating partial agonist-like interactions at site 2.</p><fig id="f3" fig-type="figure" orientation="portrait" position="float"><label>Figure 3</label><caption><title>PPAR&#947;/ NSAID interactions.</title><p>(A) Chemical structures and formulae of NSAIDs diclofenac, indomethacin and sulindac sulfide. Oxygen atoms are shaded in red, including those of the carboxylate acidic group that is a common feature of ligands that bind PPARs. (B) Superposition of NSAIDs bound to PPAR&#947;. In Chain A, the indomethacin and sulindac sulfide are bound to site 1, near H12, in a conserved binding mode, making hydrogen bonds with Y473 (H12), H449, H323 and S289, that are canonical interactions found for full agonists. In Chain B, helix 12 is an inactive conformation and sulindac sulfide bound to site 1 adopted a different bound conformation in comparison to Chain A, with interactions with Y473 and S289 not available. NSAIDs adopt different binding modes to site 2 in Chains A and B. Indomethacin and sulindac sulfide display similar binding modes at site 2 in chain A. Although indomethacin adopts the same conformation for site 2 in both chains, sulindac sulfide adopts different positions. Diclofenac is only detected at Chain B site 2 and adopts a distinct position from the other NSAIDs.</p></caption><graphic xlink:href="nrs-13-004-g3"/></fig></sec><sec><title>NSAIDs promote adipogenesis in 3T3-L1 cells</title><p>To better define the effects of NSAIDs on PPAR&#947; activity, we first determined whether they promote the PPAR&#947;-dependent adipogenic differentiation program in 3T3-L1 cells. A uniform field of fibroblasts wasinduced to differentiate with insulin, dexamethasone and isobutylxanthine in the absence or presence of rosiglitazone, which served as a positive control, or NSAIDs and then subjected to Oil Red O staining (<xref ref-type="fig" rid="f4">Figure 4A-E</xref>). This assay detects lipid staining and therefore reflects both the number of cells that have undergone adipogenic differentiation and amount of lipid in these cells. While the assay is qualitative, we noted a tendency for all NSAIDs to elicit increased lipid staining in the cells (<xref ref-type="fig" rid="f4">Figure 4C-E</xref>), as in the case of rosiglitazone (<xref ref-type="fig" rid="f4">Figure 4B</xref>). Quantitation of Oil Red O (ORO) staining on a per-cell basis supported this notion (<xref ref-type="fig" rid="f4">Figure 4F</xref>), although increases in staining obtained with ibuprofen did not meet statistical significance in this type of analysis. These results indicate that NSAIDs can elicit PPAR&#947;-dependent adipogenic effects in the 3T3-L1 differentiation assay.</p><fig id="f4" fig-type="figure" orientation="portrait" position="float"><label>Figure 4</label><caption><title>NSAIDs display adipogenic activity.</title><p>Images of 3T3-L1 cells after ligand treatment. Oil Red O staining of 3T3-L1 cells after adipocyte differentiation in the presence of: (A) DMSO vehicle control, (B) 1 &#956;M rosiglitazone, (C) 10 &#956;M indomethacin, (D) 75 &#956;M ibuprofen or (E) 25 &#956;M sodium diclofenac. Cell images are presented at 4X and 40X magnification. (F) Quantitation of Oil Red O (ORO) staining in each condition. The superscript * = P-value &lt;0.05 and *** = P-value &lt;0.01 in Students t-test.</p></caption><graphic xlink:href="nrs-13-004-g4"/></fig></sec><sec><title>NSAIDs regulate PPAR&#947; responsive genes in differentiated 3T3-L1 cells</title><p>To investigate how NSAIDs influence PPAR&#947;-dependent gene programs, we used an Illumina bead-based microarray system to analyze gene expression patterns in fully differentiated 3T3-L1 cells treated for 24 hrs with rosiglitazone or NSAIDs (<xref ref-type="fig" rid="f5">Figure 5A</xref>). We identified 277 genes regulated &#8805;2-fold by rosiglitazone and 144, 133 and 18 by indomethacin, ibuprofen and diclofenac, respectively. With the narrow exception of ibuprofen, slightly less than 50% of genes showed increased expression with each treatment, with the remainder showing decreased expression.</p><fig id="f5" fig-type="figure" orientation="portrait" position="float"><label>Figure 5</label><caption><title>NSAIDs regulate similar genes to rosiglitazone.</title><p>(A) Number of genes regulated &#8805;2 fold by rosiglitazone and NSAIDs. With the narrow exception of ibuprofen, more than 50% of genes were repressed by the treatments. (B) Shared and unique genes regulated by rosiglitazone and NSAIDs. 82.6% (119) of genes regulated by indomethacin, 76.7% (102) by ibuprofen and 100% (18) by diclofenac were also regulated by rosiglitazone more than &#8805;2 fold. (C) Percentage of genes with increased (red) and decreased (green) expression in response to rosiglitazone (R) or aggregated NSAIDs (N) in the specified functional categories: glucose metabolism, lipid metabolism, PPAR= PPAR signaling, anti-inflammatory pathway.</p></caption><graphic xlink:href="nrs-13-004-g5"/></fig><p>There was striking overlap between genes regulated by rosiglitazone and by NSAIDs. More than 80% of indomethacin responsive genes and 75% of ibuprofen responsive genes were also flagged as rosiglitazone target genes with similar directionality of response (up- or down-regulated) (<xref ref-type="fig" rid="f5">Figure 5B</xref>). All 18 diclofenac responsive genes displayed similar regulation by rosiglitazone. Accordingly, the majority of genes that respond to NSAIDs also respond to rosiglitazone, implying that NSAIDs predominantly regulate PPAR&#947; target genes in this system. We also assessed how the ligands affected genes in particular PPAR&#947; responsive pathways (<xref ref-type="fig" rid="f5">Figure 5C</xref>). To do this, we used GeneCodis [<xref rid="r8" ref-type="bibr">Carmona-Saez et al., 2007</xref>; <xref rid="r36" ref-type="bibr">Nogales-Cadenas et al., 2009</xref>; <xref rid="r53" ref-type="bibr">Tabas-Madrid et al., 2012</xref>] and the online set analysis application Venny [<xref rid="r38" ref-type="bibr">Oliveros, 2007</xref>] to group target genes according to function. This method revealed that 5.8% of rosiglitazone regulated genes relate to glucose metabolism, 9.0% to lipid metabolism, 2.9% to the PPAR signaling pathway and 10.8% to inflammatory processes. Importantly, similar proportions of NSAID responsive genes (grouped together) fell into each category and, further, similar proportions of genes in each category were up- or down-regulated by ligand. Cluster analysis confirmed that rosiglitazone and NSAIDs displayed similar effects on individual genes in each functional group (<xref ref-type="fig" rid="f6">Figure 6</xref>), but with rosiglitazone tending to display strongest responses, indomethacin and ibuprofen intermediate responses and diclofenac the weakest responses. Based on these data, rosiglitazone and NSAIDs regulate similar sets of genes and similar pathways.</p><fig id="f6" fig-type="figure" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Effects of individual NSAIDS on gene expression.</title><p>The data is presented as a cluster analysis (MultiExperiment Viewer; <ext-link ext-link-type="uri" xlink:href="http://www.tm4.org/mev/">www.tm4.org/mev/</ext-link>). Genes differentially modulated by rosiglitazone and NSAIDs within the specified functional categories are organized through hierarchical clustering. Red represents gene transcripts with increased, green decreased, and black no changes in expression level. Rosiglitazone and NSAIDs displayed similar pattern of regulation of genes involved in designated biological processes, although rosiglitazone produced a more pronounced response in comparison to NSAIDs.</p></caption><graphic xlink:href="nrs-13-004-g6"/></fig><p>We validated selected changes in target gene response by RT-qPCR (<xref ref-type="fig" rid="f7">Figure 7</xref> and not shown). Since we were unable to detect major differences in regulation of PPAR&#947;-dependent pathways in the presence of rosiglitazone and NSAIDs (<xref ref-type="fig" rid="f6">Figure 6</xref>), we focused on genes with interesting response patterns. As predicted by microarray analysis, many positively and negatively regulated genes exhibited strong responses to rosiglitazone, varying levels of intermediate response to indomethacin and ibuprofen and weakest or non-existent responses to diclofenac. Such genes included <italic>Acaa1b</italic>, which encodes an isoform of Acetyl-Coenzyme A acyltransferase 1 and <italic>Fgf21</italic>, which encodes a peptide hormone involved in adipogenic differentiation processes and systemic metabolic regulation (see <xref ref-type="fig" rid="f7">Figure 7A</xref> with others not shown).</p><fig id="f7" fig-type="figure" orientation="portrait" position="float"><label>Figure 7</label><caption><title>Validation of microarray analysis.</title><p>Gene transcripts that displayed a response to rosiglitazone and/or NSAIDs (&#8805;2.0 fold and <underline>adjusted p-value &#8804;</underline> 0.05) were analyzed by RT-qPCR. Normalized Cp values (Critical point; Cp<sub>Target</sub> - Cp<sub>18S</sub>) were analyzed by ANOVA followed by t-tests of DMSO (vehicle) vs. treatment (Bonferroni Corrected p-value &#8804; 0.05 considered significant) (GraphPad Software, version 5.01; GraphPad). * = p &#8804; 0.05, ** = p &#8804; 0.01. (A) Genes that show typical NSAID response patterns. C=DMSO control, R= Rosiglitazone, I= Indomethacin, Ib=Ibuprofen, D= Diclofenac. (B) Induced genes with unusual equivalent response to rosiglitazone and NSAIDs. (C) Repressed genes with equivalent response to rosiglitazone and NSAIDs.</p></caption><graphic xlink:href="nrs-13-004-g7"/></fig><p>We were also able to verify that some genes displayed variations in NSAID efficacy. For example, <italic>Fabp2</italic> (which encodes a protein that sequesters fatty acids) and <italic>Irs2</italic> (an insulin-signaling pathway component) displayed approximately equivalent activation by rosiglitazone and each of the NSAIDs (<xref ref-type="fig" rid="f7">Figure 7B</xref>). Further, rosiglitazone and NSAIDs displayed equivalent negative regulatory activity at Acsm3, a mitochondrial enzyme involved in fatty acid synthesis, Orm 2, an orosomucoid involved in acute phase response, Vcam1, a cell adhesion molecule involved in inflammatory response and S100a8, a calcium and zinc binding protein, also involved in inflammatory response (<xref ref-type="fig" rid="f7">Figure 7C</xref>).</p><p>Remarkably, we were unable to verify any NSAID-specific effect that was not shared with rosiglitazone (not shown). Inspection of microarray datasets and RT-qPCR analysis of 3T3-L1 transcripts that were originally flagged as uniquely NSAID responsive revealed that rosiglitazone responses simply failed to meet the 2-fold cut-off or achieve appropriate statistical significance in these cases. This finding strengthens our conclusion that NSAIDs predominantly regulate PPAR&#947; target genes in this highly PPAR&#947;-dependent system.</p><p>Finally, we confirmed that NSAID effects were dependent upon PPAR&#947; using siRNA knockdown and RT-qPCR [<xref rid="r13" ref-type="bibr">Deng et al., 2011</xref>]. Transfection of siRNA specific to PPAR&#947;, but not a scrambled control, resulted in a reduction of PPAR&#947; transcript levels by 50-75% (<xref ref-type="fig" rid="f8">Figure 8</xref>). Examination of effects of knockdown on genes that displayed strong responses to rosiglitazone and NSAID revealed that PPAR&#947; siRNA reduced or abolished rosiglitazone and indomethacin induction of Elovl3, part of the adipocyte thermogenic gene expression program, Fgf21, mentioned above, and Gyk, a glycerol kinase involved in lipid biosynthesis. These data indicate that indomethacin acts through PPAR&#947; to induce these genes.</p><fig id="f8" fig-type="figure" orientation="portrait" position="float"><label>Figure 8</label><caption><title>NSAID response requires PPAR&#947;.</title><p>Results of RT-qPCR analysis of cells treated with vehicle, rosiglitazone or indomethacin after transfection with scrambled or PPAR&#947;-specific siRNA. Data is presented as in <xref ref-type="fig" rid="f7">Figure 7</xref>. (A) Elovl3, (B) FGF21, (C) Gyk.</p></caption><graphic xlink:href="nrs-13-004-g8"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>NSAIDs display anti-inflammatory, antipyretic and analgesic properties [<xref rid="r49" ref-type="bibr">Smith et al., 1994</xref>] and fall into many chemically distinct classes, including oxicams (piroxicam), indole derivatives (indomethacin), acetic acid derivatives (diclofenac), aminoacyl carboxylic acid (flufenamic acid), arylpropionic acid (ibuprofen and fenoprofen) and acid acetylsalicylic (aspirin) [<xref rid="r43" ref-type="bibr">Rao and Knaus, 2008</xref>]. While NSAIDs work by inhibiting cyclooxygenases and blocking PG production [<xref rid="r58" ref-type="bibr">Vane et al., 1998</xref>], some of these compounds can modulate PPARs [<xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>; <xref rid="r27" ref-type="bibr">Lehmann et al., 1997b</xref>; <xref rid="r60" ref-type="bibr">Wick et al., 2002</xref>]. This finding raises the possibility that such off target NSAID effects contribute to the spectrum of actions of these drugs.</p><p>In this study, we set out to understand how PPAR&#947; interacts with different NSAIDs and to relate NSAID binding modes to influences on PPAR&#947; activity. An initial screen of NSAIDs (not shown) indicated that PPAR&#947; binds indomethacin, ibuprofen, diclofenac and sulindac sulfide <italic>in vitro</italic> and we showed that these compounds bind to PPAR&#947; with a range of affinities (sulindac sulfide&gt; diclofenac&gt; indomethacin&gt; ibuprofen). Interestingly, PPAR&#947; agonists are commonly comprised of a lipophilic backbone and an acidic moiety [<xref rid="r35" ref-type="bibr">Nettles, 2008</xref>; <xref rid="r39" ref-type="bibr">Pingali et al., 2008</xref>], usually a carboxylate, and all four NSAIDs share these characteristics [<xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>; <xref rid="r26" ref-type="bibr">Lehmann et al., 1997a</xref>; <xref rid="r60" ref-type="bibr">Wick et al., 2002</xref>]. The four NSAIDs displayed differing degrees of agonism/partial agonism in transfection assays; diclofenac exhibited weak partial agonist activity ibuprofen intermediate levels and indomethacin displayed strong partial agonist activity. General toxicity prevented us from fully assessing activities of sulindac sulfide, but results are most consistent with strong partial agonist activity. These findings agree with previous analyses. Jaradat <italic>et al.</italic> [<xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>] found that indomethacin activates PPAR&#947; more effectively than ibuprofen in CV-1 and H4IIEC3 cells. Lehmann and colleagues [<xref rid="r27" ref-type="bibr">Lehmann et al., 1997b</xref>] found that high concentrations (100 &#956;M) of ibuprofen activate PPAR&#947;, whereas other NSAIDs do not. Sulindac sulfide, toxic in our assays, has also been reported to activate PPAR&#947; [<xref rid="r60" ref-type="bibr">Wick et al., 2002</xref>], although other reports indicate that it does not [<xref rid="r47" ref-type="bibr">Sastre et al., 2006</xref>].</p><p>X-ray structures suggest possible explanations for observed NSAID activities. The diclofenac binding mode is consistent with partial agonist activity [<xref rid="r6" ref-type="bibr">Bruning et al., 2007</xref>]; diclofenac occupies site 2 and does not directly contact H12. Further, diclofenac appears better ordered in the inactive Chain B conformer and, in this regard, its interactions with PPAR&#947; resemble those of the weak partial agonist luteolin, which also binds preferentially to Chain B [29]. Diclofenac adopts different binding modes in the Chain A and Chain B LBPs and analysis of crystallographic parameters is consistent with LBD instability. In light of these findings, it is also interesting to consider the possibility that diclofenac LBP position fluctuates, like MRL20 and MRL24, and whether this could be reflected in fluctuating PPAR&#947; conformations [27, 28]. By contrast to diclofenac, indomethacin and sulindac sulfide display similar binding modes and these share features with stronger PPAR&#947; partial agonists. We detected two copies of each ligand within the active PPAR&#947; conformer (Chain A), one occupies the region near the inner surface of H12 (site 1), and the other occupies a &#8220;partial agonist&#8221; site 2 position. It seems likely that the combination of direct ligand contacts with the inner surface of H12 in site 1 and partial agonist-like interactions with H3, part of the H12 docking site, would lead to significant stabilization of H12 and account for strong partial agonism [<xref rid="r6" ref-type="bibr">Bruning et al., 2007</xref>; <xref rid="r35" ref-type="bibr">Nettles, 2008</xref>]. It is also noteworthy, however, that both NSAIDs contact Tyr473 on the inner surface of H12 through a single carboxylate group, similar to natural PPAR&#947; ligands such as fatty acids, oxidized lipids and PG J2 metabolites [<xref rid="r25" ref-type="bibr">Kliewer et al., 1995</xref>; <xref rid="r31" ref-type="bibr">Liberato et al., 2012</xref>]. The fact that this contact only partly recapitulates strong TZD contacts with Tyr473 may explain why NSAIDs do not always display full TZD-like agonist activity.</p><p>It is relatively straightforward to suggest reasons that NSAIDs do not bind PPAR&#947; as well as rosiglitazone. First, as mentioned, TZDs make tight contacts with the inner surface of H12 and nearby amino acids. Although Waku and co-workers [<xref rid="r59" ref-type="bibr">Waku et al., 2010</xref>] suggested that indole compounds interact with site 1 with higher affinity than site 2, it is clear that NSAIDs do not replicate the spectrum of TZD-like contacts within this region of the LBP. Second, rosiglitazone binds PPAR&#947; in a U-shaped conformation, occupying two sub-pockets of the Y-shaped LBP [<xref rid="r37" ref-type="bibr">Nolte et al., 1998</xref>]. NSAIDs and other smaller ligands that bind PPAR&#947; in multiple copies can occupy similar overall LBP space to TZDs, but do not bridge multiple PPAR&#947; LBP sub-pockets to link different regions of the LBD. Both factors may contribute to low affinity and some aspects of attenuated transcriptional response [<xref rid="r40" ref-type="bibr">Pochetti et al., 2007</xref>]. It is harder to assess why NSAIDs bind PPAR&#947; with different affinities. There are few obvious differences in sulindac sulfide and indomethacin binding modes that could explain a more than ten-fold difference in PPAR&#947; binding affinity (<xref ref-type="fig" rid="f1">Figure 1A</xref>). The relatively high affinity of diclofenac is also unexpected. We speculate that hydrogen bond contacts between the diclofenac carboxylate and the Ser342 side chain at site 2 may contribute significantly to the affinity of this ligand for PPAR&#947;. It will be interesting to test this theory in molecular dynamics simulations.</p><p>In general, NSAID effects in the PPAR&#947;-dependent 3T3-L1 system agreed well with predictions from crystal structures. Indomethacin, ibuprofen and diclofenac promoted adipocyte differentiation, as judged by Oil Red O staining, as previously established for classic PPAR&#947; agonists such as Rosiglitazone, which was included here as a positive control. Further, gene expression analysis after treatment of (mature) adipocytes with NSAIDs showed extensive overlaps with rosiglitazone target genes (<xref ref-type="fig" rid="f5">Figure 5</xref> and <xref ref-type="fig" rid="f6">Figure 6</xref>). However, analyses of numbers of target genes regulated (<xref ref-type="fig" rid="f5">Figure 5A</xref>) and individual gene expression patterns (<xref ref-type="fig" rid="f6">Figure 6</xref> and <xref ref-type="fig" rid="f7">Figure 7A</xref>) indicate that NSAIDs are weaker than rosiglitazone and that indomethacin and ibuprofen are stronger partial agonists than diclofenac.</p><p>There were some instances in which we observed gene-specific NSAID activities. For example, indomethacin, ibuprofen and diclofenac activated the <italic>Fabp5</italic> and <italic>Irs2</italic> genes as efficiently as rosiglitazone and NSAIDs repressed transcription of several genes as effectively as rosiglitazone. Most PPAR&#947; ligands, including compounds that bind exclusively to site 2, stabilize the &#946;-sheet region and block an inhibitory phosphorylation at Ser273 [<xref rid="r9" ref-type="bibr">Choi et al., 2010</xref>; <xref rid="r10" ref-type="bibr">Choi et al., 2011</xref>]. Ligands that stabilize the &#946;-sheet without stabilizing H12 can induce genes that are particularly sensitive to inhibitory effects of Ser273 phosphorylation and it is interesting to speculate that this phenomenon could explain some instances of high gene-specific NSAID efficacy.</p><p>Importantly, our studies suggest that NSAIDs only regulate PPAR&#947; responsive genes in this system. This raises the possibility that NSAIDs could trigger PPAR&#947; responsive gene programs in adipocytes and, possibly, in other cell types. We certainly think that it is possible that NSAIDs could activate PPARs at pharmacologically-relevant doses. Indomethacin, a <italic>racemic</italic> (RS-mixture) of ibuprofen, sodium diclofenac and the prodrug sulindac are all used clinically [<xref rid="r7" ref-type="bibr">Bushra and Aslam, 2010</xref>; <xref rid="r12" ref-type="bibr">Davies and Anderson, 1997</xref>; <xref rid="r51" ref-type="bibr">Smyth et al., 2004</xref>; <xref rid="r55" ref-type="bibr">Thun et al., 2002</xref>]. COX inhibitors relieve pain and inflammation caused by PG synthesis [<xref rid="r49" ref-type="bibr">Smith et al., 1994</xref>]. However, high doses are usually required for palliation of other conditions, including rheumatoid arthritis. Here, required therapeutic plasma concentrations are up to 10 &#956;M indomethacin, 20 &#956;M sulindac or 300 &#956;M ibuprofen [<xref rid="r32" ref-type="bibr">McEvoy, 1997</xref>] and exceed those required to inhibit COX-1 and 2 [<xref rid="r33" ref-type="bibr">Meade et al., 1993</xref>]. Perhaps NSAIDs activate PPAR&#947; (or PPAR&#945;) to achieve some of these effects. Fish oil supplements, rich in unsaturated fatty acids, may also decrease the inflammatory response and reduce symptoms of rheumatoid arthritis, and docosahexanoic acid in this oil is a natural PPAR&#947; agonist [<xref rid="r61" ref-type="bibr">Ye, 2011</xref>]. Another factor could favor NSAID actions through PPAR&#947;; rosiglitazone and other NSAIDs are highly albumin bound in serum [63]. Very high doses of ibuprofen are used to treat rheumatoid arthritis and these concentrations are sufficient to escape from the inhibitory influence of serum albumin. Use of these drugs at high concentrations could result in significant levels of free drug, available for both on- and off-target interactions. In this regard, it is important to note that ligand treatments in transfection experiments described in <xref ref-type="fig" rid="f1">Figure 1B</xref> were performed in 10% serum; accordingly, observed NSAID dose responses were not obtained in completely BSA-free conditions. Perhaps high concentrations of NSAID could permit escape of free drug and increased activities through PPARs.</p><p>Our findings, which indicate that NSAIDs display diverse binding modes and effects on PPAR activity, coupled with other studies which show that some NSAIDs activate PPARs while others with strong anti-inflammatory activities do not [<xref rid="r21" ref-type="bibr">Jaradat et al., 2001</xref>; <xref rid="r26" ref-type="bibr">Lehmann et al., 1997a</xref>], suggest that questions of whether particular NSAIDs modulate PPARs must be approached on a case-by-case basis. NSAIDs are attractive compounds for design of new drugs because their pharmacokinetics are extensively studied in humans, and it may be possible to engineer altered specificity for COX and PPARs into existing drugs. For example, removal of the sulindac sulfide indenyl methyl group abolishes COX inhibitory activities while retaining activity at other targets, including PPAR&#947; [<xref rid="r16" ref-type="bibr">Felts et al., 2007</xref>]. It will be interesting to determine whether high doses of particular NSAIDs do result in significant PPAR activation, whether this interaction is associated with beneficial anti-inflammatory effects or harmful side effects, and whether it will be desirable to create novel analogs with PPAR-dependent activities.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by NIH DK41482 to PW.</p></ack><fn-group><fn fn-type="COI-statement"><p>The authors declare no competing interests.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>P. D.</given-names></name><name><surname>Afonine</surname><given-names>P. V.</given-names></name><name><surname>Bunk&#243;czi</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>V. B.</given-names></name><name><surname>Davis</surname><given-names>I. W.</given-names></name><name><surname>Echols</surname><given-names>N.</given-names></name><name><surname>Headd</surname><given-names>J. J.</given-names></name><name><surname>Hung</surname><given-names>L. W.</given-names></name><name><surname>Kapral</surname><given-names>G. J.</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>R. W.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution.</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<volume>66</volume>, <fpage>213</fpage>-<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><?supplied-pmid 20124702?><pub-id pub-id-type="pmid">20124702</pub-id></mixed-citation></ref><ref id="r2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y.</given-names></name><name><surname>Hochberg</surname><given-names>Y.</given-names></name></person-group> (<year>1995</year>). <article-title>CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING.</article-title>
<source>Journal of the Royal Statistical Society Series B-Methodological</source>
<volume>57</volume>, <fpage>289</fpage>-<lpage>300</lpage>.</mixed-citation></ref><ref id="r3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>J.</given-names></name><name><surname>Moller</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>). <article-title>The mechanisms of action of PPARs.</article-title>
<source>Annu Rev Med</source>
<volume>53</volume>, <fpage>409</fpage>-<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.med.53.082901.104018</pub-id><?supplied-pmid 11818483?><pub-id pub-id-type="pmid">11818483</pub-id></mixed-citation></ref><ref id="r4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braissant</surname><given-names>O.</given-names></name><name><surname>Foufelle</surname><given-names>F.</given-names></name><name><surname>Scotto</surname><given-names>C.</given-names></name><name><surname>Dau&#231;a</surname><given-names>M.</given-names></name><name><surname>Wahli</surname><given-names>W.</given-names></name></person-group> (<year>1996</year>). <article-title>Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.</article-title>
<source>Endocrinology</source>
<volume>137</volume>, <fpage>354</fpage>-<lpage>366</lpage>.<?supplied-pmid 8536636?><pub-id pub-id-type="pmid">8536636</pub-id></mixed-citation></ref><ref id="r5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brune</surname><given-names>K.</given-names></name><name><surname>Beck</surname><given-names>W. S.</given-names></name><name><surname>Geisslinger</surname><given-names>G.</given-names></name><name><surname>Menzel-Soglowek</surname><given-names>S.</given-names></name><name><surname>Peskar</surname><given-names>B. M.</given-names></name><name><surname>Peskar</surname><given-names>B. A.</given-names></name></person-group> (<year>1991</year>). <article-title>Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition.</article-title>
<source>Experientia</source>
<volume>47</volume>, <fpage>257</fpage>-<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1007/BF01958153</pub-id><?supplied-pmid 2009936?><pub-id pub-id-type="pmid">2009936</pub-id></mixed-citation></ref><ref id="r6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruning</surname><given-names>J. B.</given-names></name><name><surname>Chalmers</surname><given-names>M. J.</given-names></name><name><surname>Prasad</surname><given-names>S.</given-names></name><name><surname>Busby</surname><given-names>S. A.</given-names></name><name><surname>Kamenecka</surname><given-names>T. M.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Nettles</surname><given-names>K. W.</given-names></name><name><surname>Griffin</surname><given-names>P. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Partial agonists activate PPARgamma using a helix 12 independent mechanism.</article-title>
<source>Structure</source>
<volume>15</volume>, <fpage>1258</fpage>-<lpage>1271</lpage>.<?supplied-pmid 17937915?><pub-id pub-id-type="pmid">17937915</pub-id></mixed-citation></ref><ref id="r7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushra</surname><given-names>R.</given-names></name><name><surname>Aslam</surname><given-names>N.</given-names></name></person-group> (<year>2010</year>). <article-title>An overview of clinical pharmacology of Ibuprofen.</article-title>
<source>Oman Med J</source>
<volume>25</volume>, <fpage>155</fpage>-<lpage>1661</lpage>.<?supplied-pmid 22043330?><pub-id pub-id-type="pmid">22043330</pub-id></mixed-citation></ref><ref id="r8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona-Saez</surname><given-names>P.</given-names></name><name><surname>Chagoyen</surname><given-names>M.</given-names></name><name><surname>Tirado</surname><given-names>F.</given-names></name><name><surname>Carazo</surname><given-names>J. M.</given-names></name><name><surname>Pascual-Montano</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists.</article-title>
<source>Genome Biol</source>
<volume>8</volume>, <fpage>R3</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2007-8-1-r3</pub-id><?supplied-pmid 17204154?><pub-id pub-id-type="pmid">17204154</pub-id></mixed-citation></ref><ref id="r9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J. H.</given-names></name><name><surname>Banks</surname><given-names>A. S.</given-names></name><name><surname>Estall</surname><given-names>J. L.</given-names></name><name><surname>Kajimura</surname><given-names>S.</given-names></name><name><surname>Bostr&#246;m</surname><given-names>P.</given-names></name><name><surname>Laznik</surname><given-names>D.</given-names></name><name><surname>Ruas</surname><given-names>J. L.</given-names></name><name><surname>Chalmers</surname><given-names>M. J.</given-names></name><name><surname>Kamenecka</surname><given-names>T. M.</given-names></name><name><surname>Bl&#252;her</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.</article-title>
<source>Nature</source>
<volume>466</volume>, <fpage>451</fpage>-<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1038/nature09291</pub-id><?supplied-pmid 20651683?><pub-id pub-id-type="pmid">20651683</pub-id></mixed-citation></ref><ref id="r10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J. H.</given-names></name><name><surname>Banks</surname><given-names>A. S.</given-names></name><name><surname>Kamenecka</surname><given-names>T. M.</given-names></name><name><surname>Busby</surname><given-names>S. A.</given-names></name><name><surname>Chalmers</surname><given-names>M. J.</given-names></name><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Kuruvilla</surname><given-names>D. S.</given-names></name><name><surname>Shin</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Bruning</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Antidiabetic actions of a non-agonist PPAR&#947; ligand blocking Cdk5-mediated phosphorylation.</article-title>
<source>Nature</source>
<volume>477</volume>, <fpage>477</fpage>-<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1038/nature10383</pub-id><?supplied-pmid 21892191?><pub-id pub-id-type="pmid">21892191</pub-id></mixed-citation></ref><ref id="r11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Collaborative Computational Project</collab></person-group>, N. m. (<year>1994</year>). <article-title>The CCP4 suite: programs for protein crystallography.</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<volume>50</volume>, <fpage>760</fpage>-<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444994003112</pub-id><?supplied-pmid 15299374?><pub-id pub-id-type="pmid">15299374</pub-id></mixed-citation></ref><ref id="r12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>N. M.</given-names></name><name><surname>Anderson</surname><given-names>K. E.</given-names></name></person-group> (<year>1997</year>). <article-title>Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.</article-title>
<source>Clin Pharmacokinet</source>
<volume>33</volume>, <fpage>184</fpage>-<lpage>213</lpage>. <pub-id pub-id-type="doi">10.2165/00003088-199733030-00003</pub-id><?supplied-pmid 9314611?><pub-id pub-id-type="pmid">9314611</pub-id></mixed-citation></ref><ref id="r13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Sieglaff</surname><given-names>D. H.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Lyon</surname><given-names>C. J.</given-names></name><name><surname>Ayers</surname><given-names>S. D.</given-names></name><name><surname>Cvoro</surname><given-names>A.</given-names></name><name><surname>Gupte</surname><given-names>A. A.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name><name><surname>Baxter</surname><given-names>J. D.</given-names></name><name><surname>Webb</surname><given-names>P.</given-names></name><name><surname>Hsueh</surname><given-names>W. A.</given-names></name></person-group> (<year>2011</year>). <article-title>A peroxisome proliferator-activated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function.</article-title>
<source>J Biol Chem</source>
<volume>286</volume>, <fpage>30723</fpage>-<lpage>30731</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.251926</pub-id><?supplied-pmid 21719705?><pub-id pub-id-type="pmid">21719705</pub-id></mixed-citation></ref><ref id="r14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>P.</given-names></name><name><surname>Kibbe</surname><given-names>W. A.</given-names></name><name><surname>Lin</surname><given-names>S. M.</given-names></name></person-group> (<year>2008</year>). <article-title>lumi: a pipeline for processing Illumina microarray.</article-title>
<source>Bioinformatics</source>
<volume>24</volume>, <fpage>1547</fpage>-<lpage>1548</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btn224</pub-id><?supplied-pmid 18467348?><pub-id pub-id-type="pmid">18467348</pub-id></mixed-citation></ref><ref id="r15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Cowtan</surname><given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Coot: model-building tools for molecular graphics.</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<volume>60</volume>, <fpage>2126</fpage>-<lpage>2132</lpage>. <pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><?supplied-pmid 15572765?><pub-id pub-id-type="pmid">15572765</pub-id></mixed-citation></ref><ref id="r16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felts</surname><given-names>A. S.</given-names></name><name><surname>Ji</surname><given-names>C.</given-names></name><name><surname>Stafford</surname><given-names>J. B.</given-names></name><name><surname>Crews</surname><given-names>B. C.</given-names></name><name><surname>Kingsley</surname><given-names>P. J.</given-names></name><name><surname>Rouzer</surname><given-names>C. A.</given-names></name><name><surname>Washington</surname><given-names>M. K.</given-names></name><name><surname>Subbaramaiah</surname><given-names>K.</given-names></name><name><surname>Siegel</surname><given-names>B. S.</given-names></name><name><surname>Young</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology.</article-title>
<source>ACS Chem Biol</source>
<volume>2</volume>, <fpage>479</fpage>-<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1021/cb700077z</pub-id><?supplied-pmid 17602619?><pub-id pub-id-type="pmid">17602619</pub-id></mixed-citation></ref><ref id="r17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forman</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Evans</surname><given-names>R.</given-names></name></person-group> (<year>1996</year>). <article-title>The peroxisome proliferator-activated receptors: ligands and activators.</article-title>
<source>Ann N Y Acad Sci</source>
<volume>804</volume>, <fpage>266</fpage>-<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1996.tb18621.x</pub-id><?supplied-pmid 8993549?><pub-id pub-id-type="pmid">8993549</pub-id></mixed-citation></ref><ref id="r18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilroy</surname><given-names>D. W.</given-names></name><name><surname>Colville-Nash</surname><given-names>P. R.</given-names></name></person-group> (<year>2000</year><comment>a</comment>). <article-title>New insights into the role of COX 2 in inflammation.</article-title>
<source>Journal of Molecular Medicine (Berlin, Germany)</source>
<volume>78</volume>, <fpage>121</fpage>-<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1007/s001090000094</pub-id><?supplied-pmid 10868474?><pub-id pub-id-type="pmid">10868474</pub-id></mixed-citation></ref><ref id="r19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilroy</surname><given-names>D. W.</given-names></name><name><surname>Colville-Nash</surname><given-names>P. R.</given-names></name></person-group> (<year>2000</year><comment>b</comment>). <article-title>New insights into the role of COX 2 in inflammation.</article-title>
<source>J Mol Med (Berl)</source>
<volume>78</volume>, <fpage>121</fpage>-<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1007/s001090000094</pub-id><?supplied-pmid 10868474?><pub-id pub-id-type="pmid">10868474</pub-id></mixed-citation></ref><ref id="r20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimar&#227;es</surname><given-names>B. G.</given-names></name><name><surname>Sanfelici</surname><given-names>L.</given-names></name><name><surname>Neuenschwander</surname><given-names>R. T.</given-names></name><name><surname>Rodrigues</surname><given-names>F.</given-names></name><name><surname>Grizolli</surname><given-names>W. C.</given-names></name><name><surname>Raulik</surname><given-names>M. A.</given-names></name><name><surname>Piton</surname><given-names>J. R.</given-names></name><name><surname>Meyer</surname><given-names>B. C.</given-names></name><name><surname>Nascimento</surname><given-names>A. S.</given-names></name><name><surname>Polikarpov</surname><given-names>I.</given-names></name></person-group> (<year>2009</year>). <article-title>The MX2 macromolecular crystallography beamline: a wiggler X-ray source at the LNLS.</article-title>
<source>J Synchrotron Radiat</source>
<volume>16</volume>, <fpage>69</fpage>-<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1107/S0909049508034870</pub-id><?supplied-pmid 19096177?><pub-id pub-id-type="pmid">19096177</pub-id></mixed-citation></ref><ref id="r21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaradat</surname><given-names>M. S.</given-names></name><name><surname>Wongsud</surname><given-names>B.</given-names></name><name><surname>Phornchirasilp</surname><given-names>S.</given-names></name><name><surname>Rangwala</surname><given-names>S. M.</given-names></name><name><surname>Shams</surname><given-names>G.</given-names></name><name><surname>Sutton</surname><given-names>M.</given-names></name><name><surname>Romstedt</surname><given-names>K. J.</given-names></name><name><surname>Noonan</surname><given-names>D. J.</given-names></name><name><surname>Feller</surname><given-names>D. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin.</article-title>
<source>Biochem Pharmacol</source>
<volume>62</volume>, <fpage>1587</fpage>-<lpage>1595</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(01)00822-X</pub-id><?supplied-pmid 11755111?><pub-id pub-id-type="pmid">11755111</pub-id></mixed-citation></ref><ref id="r22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Ting</surname><given-names>A. T.</given-names></name><name><surname>Seed</surname><given-names>B.</given-names></name></person-group> (<year>1998</year>). <article-title>PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.</article-title>
<source>Nature</source>
<volume>391</volume>, <fpage>82</fpage>-<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1038/35154</pub-id><?supplied-pmid 9422509?><pub-id pub-id-type="pmid">9422509</pub-id></mixed-citation></ref><ref id="r23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemm</surname><given-names>D. J.</given-names></name><name><surname>Leitner</surname><given-names>J. W.</given-names></name><name><surname>Watson</surname><given-names>P.</given-names></name><name><surname>Nesterova</surname><given-names>A.</given-names></name><name><surname>Reusch</surname><given-names>J. E.</given-names></name><name><surname>Goalstone</surname><given-names>M. L.</given-names></name><name><surname>Draznin</surname><given-names>B.</given-names></name></person-group> (<year>2001</year>). <article-title>Insulin-induced adipocyte differentiation. Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation.</article-title>
<source>J Biol Chem</source>
<volume>276</volume>, <fpage>28430</fpage>-<lpage>28435</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M103382200</pub-id><?supplied-pmid 11375992?><pub-id pub-id-type="pmid">11375992</pub-id></mixed-citation></ref><ref id="r24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kliewer</surname><given-names>S.</given-names></name><name><surname>Forman</surname><given-names>B.</given-names></name><name><surname>Blumberg</surname><given-names>B.</given-names></name><name><surname>Ong</surname><given-names>E.</given-names></name><name><surname>Borgmeyer</surname><given-names>U.</given-names></name><name><surname>Mangelsdorf</surname><given-names>D.</given-names></name><name><surname>Umesono</surname><given-names>K.</given-names></name><name><surname>Evans</surname><given-names>R.</given-names></name></person-group> (<year>1994</year>). <article-title>Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>91</volume>, <fpage>7355</fpage>-<lpage>7359</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.91.15.7355</pub-id><?supplied-pmid 8041794?><pub-id pub-id-type="pmid">8041794</pub-id></mixed-citation></ref><ref id="r25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kliewer</surname><given-names>S. A.</given-names></name><name><surname>Lenhard</surname><given-names>J. M.</given-names></name><name><surname>Willson</surname><given-names>T. M.</given-names></name><name><surname>Patel</surname><given-names>I.</given-names></name><name><surname>Morris</surname><given-names>D. C.</given-names></name><name><surname>Lehmann</surname><given-names>J. M.</given-names></name></person-group> (<year>1995</year>). <article-title>A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.</article-title>
<source>Cell</source>
<volume>83</volume>, <fpage>813</fpage>-<lpage>819</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(95)90194-9</pub-id><?supplied-pmid 8521498?><pub-id pub-id-type="pmid">8521498</pub-id></mixed-citation></ref><ref id="r26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>J.</given-names></name><name><surname>Lenhard</surname><given-names>J.</given-names></name><name><surname>Oliver</surname><given-names>B.</given-names></name><name><surname>Ringold</surname><given-names>G.</given-names></name><name><surname>Kliewer</surname><given-names>S.</given-names></name></person-group> (<year>1997</year><comment>a</comment>). <article-title>Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.</article-title>
<source>J Biol Chem</source>
<volume>272</volume>, <fpage>3406</fpage>-<lpage>3410</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.6.3406</pub-id><?supplied-pmid 9013583?><pub-id pub-id-type="pmid">9013583</pub-id></mixed-citation></ref><ref id="r27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>J.</given-names></name><name><surname>Lenhard</surname><given-names>J.</given-names></name><name><surname>Oliver</surname><given-names>B.</given-names></name><name><surname>Ringold</surname><given-names>G.</given-names></name><name><surname>Kliewer</surname><given-names>S.</given-names></name></person-group> (<year>1997</year><comment>b</comment>). <article-title>Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.</article-title>
<source>Journal of Biological Chemistry</source>
<volume>272</volume>, <fpage>3406</fpage>-<lpage>3410</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.6.3406</pub-id><?supplied-pmid 9013583?><pub-id pub-id-type="pmid">9013583</pub-id></mixed-citation></ref><ref id="r28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrke</surname><given-names>M.</given-names></name><name><surname>Lazar</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>The many faces of PPARgamma.</article-title>
<source>Cell</source>
<volume>123</volume>, <fpage>993</fpage>-<lpage>999</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2005.11.026</pub-id><?supplied-pmid 16360030?><pub-id pub-id-type="pmid">16360030</pub-id></mixed-citation></ref><ref id="r29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>A. G.</given-names></name></person-group> (<year>1999</year>). <article-title>Integration of macromolecular diffraction data.</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<volume>55</volume>, <fpage>1696</fpage>-<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1107/S090744499900846X</pub-id><?supplied-pmid 10531519?><pub-id pub-id-type="pmid">10531519</pub-id></mixed-citation></ref><ref id="r30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M. D.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group> (<year>2011</year>). <article-title>A Retrospective on Nuclear Receptor Regulation of Inflammation: Lessons from GR and PPARs.</article-title>
<source>PPAR Res</source>
<volume>2011</volume>, <fpage>742785</fpage>. <pub-id pub-id-type="doi">10.1155/2011/742785</pub-id><?supplied-pmid 21941526?><pub-id pub-id-type="pmid">21941526</pub-id></mixed-citation></ref><ref id="r31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberato</surname><given-names>M. V.</given-names></name><name><surname>Nascimento</surname><given-names>A. S.</given-names></name><name><surname>Ayers</surname><given-names>S. D.</given-names></name><name><surname>Lin</surname><given-names>J. Z.</given-names></name><name><surname>Cvoro</surname><given-names>A.</given-names></name><name><surname>Silveira</surname><given-names>R. L.</given-names></name><name><surname>Mart&#237;nez</surname><given-names>L.</given-names></name><name><surname>Souza</surname><given-names>P. C.</given-names></name><name><surname>Saidemberg</surname><given-names>D.</given-names></name><name><surname>Deng</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) &#947; activators and pan-PPAR partial agonists.</article-title>
<source>PLoS One</source>
<volume>7</volume>, <fpage>e36297</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0036297</pub-id><?supplied-pmid 22649490?><pub-id pub-id-type="pmid">22649490</pub-id></mixed-citation></ref><ref id="r32"><mixed-citation publication-type="book">McEvoy, G. K. (1997). AHFS 97 Drug Information (Bethesda, MD, American Society of Health - Systems Pharmacists).</mixed-citation></ref><ref id="r33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meade</surname><given-names>E. A.</given-names></name><name><surname>Smith</surname><given-names>W. L.</given-names></name><name><surname>DeWitt</surname><given-names>D. L.</given-names></name></person-group> (<year>1993</year>). <article-title>Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs.</article-title>
<source>J Biol Chem</source>
<volume>268</volume>, <fpage>6610</fpage>-<lpage>6614</lpage>.<?supplied-pmid 8454631?><pub-id pub-id-type="pmid">8454631</pub-id></mixed-citation></ref><ref id="r34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>A.</given-names></name><name><surname>Hale</surname><given-names>V. G.</given-names></name><name><surname>Borga</surname><given-names>O.</given-names></name><name><surname>Stein</surname><given-names>R.</given-names></name></person-group> (<year>1996</year>). <article-title>Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats.</article-title>
<source>Inflamm Res</source>
<volume>45</volume>, <fpage>531</fpage>-<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1007/BF02342223</pub-id><?supplied-pmid 8951503?><pub-id pub-id-type="pmid">8951503</pub-id></mixed-citation></ref><ref id="r35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nettles</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Insights into PPARgamma from structures with endogenous and covalently bound ligands.</article-title>
<source>Nat Struct Mol Biol</source>
<volume>15</volume>, <fpage>893</fpage>-<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb0908-893</pub-id><?supplied-pmid 18769464?><pub-id pub-id-type="pmid">18769464</pub-id></mixed-citation></ref><ref id="r36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales-Cadenas</surname><given-names>R.</given-names></name><name><surname>Carmona-Saez</surname><given-names>P.</given-names></name><name><surname>Vazquez</surname><given-names>M.</given-names></name><name><surname>Vicente</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Tirado</surname><given-names>F.</given-names></name><name><surname>Carazo</surname><given-names>J. M.</given-names></name><name><surname>Pascual-Montano</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information.</article-title>
<source>Nucleic Acids Res</source>
<volume>37</volume>, <fpage>W317-322</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkp416</pub-id><?supplied-pmid 19465387?><pub-id pub-id-type="pmid">19465387</pub-id></mixed-citation></ref><ref id="r37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>R.</given-names></name><name><surname>Wisely</surname><given-names>G.</given-names></name><name><surname>Westin</surname><given-names>S.</given-names></name><name><surname>Cobb</surname><given-names>J.</given-names></name><name><surname>Lambert</surname><given-names>M.</given-names></name><name><surname>Kurokawa</surname><given-names>R.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.</given-names></name><name><surname>Willson</surname><given-names>T.</given-names></name><name><surname>Glass</surname><given-names>C.</given-names></name><name><surname>Milburn</surname><given-names>M.</given-names></name></person-group> (<year>1998</year>). <article-title>Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.</article-title>
<source>Nature</source>
<volume>395</volume>, <fpage>137</fpage>-<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1038/25931</pub-id><?supplied-pmid 9744270?><pub-id pub-id-type="pmid">9744270</pub-id></mixed-citation></ref><ref id="r38"><mixed-citation publication-type="web">Oliveros, J. C. (2007). VENNY. An interactive tool for comparing lists with venn diagrams (<ext-link ext-link-type="uri" xlink:href="http://bioinfogp.cnb.csic.es/tools/venny/index.html">http://bioinfogp.cnb.csic.es/tools/venny/index.html</ext-link>.).</mixed-citation></ref><ref id="r39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pingali</surname><given-names>H.</given-names></name><name><surname>Jain</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Patil</surname><given-names>P.</given-names></name><name><surname>Makadia</surname><given-names>P.</given-names></name><name><surname>Zaware</surname><given-names>P.</given-names></name><name><surname>Sairam</surname><given-names>K. V.</given-names></name><name><surname>Jamili</surname><given-names>J.</given-names></name><name><surname>Goel</surname><given-names>A.</given-names></name><name><surname>Patel</surname><given-names>M.</given-names></name><name><surname>Patel</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety.</article-title>
<source>Bioorg Med Chem Lett</source>
<volume>18</volume>, <fpage>6471</fpage>-<lpage>6475</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2008.10.062</pub-id><?supplied-pmid 18976908?><pub-id pub-id-type="pmid">18976908</pub-id></mixed-citation></ref><ref id="r40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pochetti</surname><given-names>G.</given-names></name><name><surname>Godio</surname><given-names>C.</given-names></name><name><surname>Mitro</surname><given-names>N.</given-names></name><name><surname>Caruso</surname><given-names>D.</given-names></name><name><surname>Galmozzi</surname><given-names>A.</given-names></name><name><surname>Scurati</surname><given-names>S.</given-names></name><name><surname>Loiodice</surname><given-names>F.</given-names></name><name><surname>Fracchiolla</surname><given-names>G.</given-names></name><name><surname>Tortorella</surname><given-names>P.</given-names></name><name><surname>Laghezza</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.</article-title>
<source>Journal of Biological Chemistry</source>
<volume>282</volume>, <fpage>17314</fpage>-<lpage>17324</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M702316200</pub-id><?supplied-pmid 17403688?><pub-id pub-id-type="pmid">17403688</pub-id></mixed-citation></ref><ref id="r41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pountos</surname><given-names>I.</given-names></name><name><surname>Giannoudis</surname><given-names>P. V.</given-names></name><name><surname>Jones</surname><given-names>E.</given-names></name><name><surname>English</surname><given-names>A.</given-names></name><name><surname>Churchman</surname><given-names>S.</given-names></name><name><surname>Field</surname><given-names>S.</given-names></name><name><surname>Ponchel</surname><given-names>F.</given-names></name><name><surname>Bird</surname><given-names>H.</given-names></name><name><surname>Emery</surname><given-names>P.</given-names></name><name><surname>McGonagle</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis: implications for mechanism of bone formation inhibition in man.</article-title>
<source>J Cell Mol Med</source>
<volume>15</volume>, <fpage>525</fpage>-<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2010.01006.x</pub-id><?supplied-pmid 20070439?><pub-id pub-id-type="pmid">20070439</pub-id></mixed-citation></ref><ref id="r42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puhl</surname><given-names>A. C.</given-names></name><name><surname>Bernardes</surname><given-names>A.</given-names></name><name><surname>Silveira</surname><given-names>R. L.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Campos</surname><given-names>J. L.</given-names></name><name><surname>Saidemberg</surname><given-names>D. M.</given-names></name><name><surname>Palma</surname><given-names>M. S.</given-names></name><name><surname>Cvoro</surname><given-names>A.</given-names></name><name><surname>Ayers</surname><given-names>S. D.</given-names></name><name><surname>Webb</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Mode of Peroxisome Proliferator-Activated Receptor &#947; Activation by Luteolin.</article-title>
<source>Mol Pharmacol</source>
<volume>81</volume>, <fpage>788</fpage>-<lpage>799</lpage>. <pub-id pub-id-type="doi">10.1124/mol.111.076216</pub-id><?supplied-pmid 22391103?><pub-id pub-id-type="pmid">22391103</pub-id></mixed-citation></ref><ref id="r43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>P.</given-names></name><name><surname>Knaus</surname><given-names>E. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.</article-title>
<source>J Pharm Pharm Sci</source>
<volume>11</volume>, <fpage>81s</fpage>-<lpage>110s</lpage>.<?supplied-pmid 19203472?><pub-id pub-id-type="pmid">19203472</pub-id></mixed-citation></ref><ref id="r44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Welch</surname><given-names>J.</given-names></name><name><surname>Najib</surname><given-names>J.</given-names></name><name><surname>Witztum</surname><given-names>J. L.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name><name><surname>Palinski</surname><given-names>W.</given-names></name><name><surname>Glass</surname><given-names>C. K.</given-names></name></person-group> (<year>1998</year><comment>a</comment>). <article-title>Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>95</volume>, <fpage>7614</fpage>-<lpage>7619</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.13.7614</pub-id><?supplied-pmid 9636198?><pub-id pub-id-type="pmid">9636198</pub-id></mixed-citation></ref><ref id="r45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>A. C.</given-names></name><name><surname>Willson</surname><given-names>T. M.</given-names></name><name><surname>Kelly</surname><given-names>C. J.</given-names></name><name><surname>Glass</surname><given-names>C. K.</given-names></name></person-group> (<year>1998</year><comment>b</comment>). <article-title>The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.</article-title>
<source>Nature</source>
<volume>391</volume>, <fpage>79</fpage>-<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1038/34178</pub-id><?supplied-pmid 9422508?><pub-id pub-id-type="pmid">9422508</pub-id></mixed-citation></ref><ref id="r46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricote</surname><given-names>M.</given-names></name><name><surname>Welch</surname><given-names>J. S.</given-names></name><name><surname>Glass</surname><given-names>C. K.</given-names></name></person-group> (<year>2000</year>). <article-title>Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma.</article-title>
<source>Horm Res</source>
<volume>54</volume>, <fpage>275</fpage>-<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1159/000053271</pub-id><?supplied-pmid 11595817?><pub-id pub-id-type="pmid">11595817</pub-id></mixed-citation></ref><ref id="r47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastre</surname><given-names>M.</given-names></name><name><surname>Dewachter</surname><given-names>I.</given-names></name><name><surname>Rossner</surname><given-names>S.</given-names></name><name><surname>Bogdanovic</surname><given-names>N.</given-names></name><name><surname>Rosen</surname><given-names>E.</given-names></name><name><surname>Borghgraef</surname><given-names>P.</given-names></name><name><surname>Evert</surname><given-names>B. O.</given-names></name><name><surname>Dumitrescu-Ozimek</surname><given-names>L.</given-names></name><name><surname>Thal</surname><given-names>D. R.</given-names></name><name><surname>Landreth</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>103</volume>, <fpage>443</fpage>-<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0503839103</pub-id><?supplied-pmid 16407166?><pub-id pub-id-type="pmid">16407166</pub-id></mixed-citation></ref><ref id="r48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoonjans</surname><given-names>K.</given-names></name><name><surname>Martin</surname><given-names>G.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name><name><surname>Auwerx</surname><given-names>J.</given-names></name></person-group> (<year>1997</year>). <article-title>Peroxisome proliferator-activated receptors, orphans with ligands and functions.</article-title>
<source>Curr Opin Lipidol</source>
<volume>8</volume>, <fpage>159</fpage>-<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1097/00041433-199706000-00006</pub-id><?supplied-pmid 9211064?><pub-id pub-id-type="pmid">9211064</pub-id></mixed-citation></ref><ref id="r49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>W. L.</given-names></name><name><surname>Meade</surname><given-names>E. A.</given-names></name><name><surname>DeWitt</surname><given-names>D. L.</given-names></name></person-group> (<year>1994</year>). <article-title>Interactions of PGH synthase isozymes-1 and -2 with NSAIDs.</article-title>
<source>Annals of the New York Academy of Sciences</source>
<volume>744</volume>, <fpage>50</fpage>-<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1994.tb52723.x</pub-id><?supplied-pmid 7825862?><pub-id pub-id-type="pmid">7825862</pub-id></mixed-citation></ref><ref id="r50"><mixed-citation publication-type="other">Smyth, G. K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. <italic>Stat Appl Genet Mol Biol</italic>
<bold>3</bold>, Article3.</mixed-citation></ref><ref id="r51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>J. M.</given-names></name><name><surname>Collier</surname><given-names>P. S.</given-names></name><name><surname>Darwish</surname><given-names>M.</given-names></name><name><surname>Millership</surname><given-names>J. S.</given-names></name><name><surname>Halliday</surname><given-names>H. L.</given-names></name><name><surname>Petersen</surname><given-names>S.</given-names></name><name><surname>McElnay</surname><given-names>J. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.</article-title>
<source>Br J Clin Pharmacol</source>
<volume>58</volume>, <fpage>249</fpage>-<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2004.02139.x</pub-id><?supplied-pmid 15327584?><pub-id pub-id-type="pmid">15327584</pub-id></mixed-citation></ref><ref id="r52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staels</surname><given-names>B.</given-names></name><name><surname>Koenig</surname><given-names>W.</given-names></name><name><surname>Habib</surname><given-names>A.</given-names></name><name><surname>Merval</surname><given-names>R.</given-names></name><name><surname>Lebret</surname><given-names>M.</given-names></name><name><surname>Torra</surname><given-names>I. P.</given-names></name><name><surname>Delerive</surname><given-names>P.</given-names></name><name><surname>Fadel</surname><given-names>A.</given-names></name><name><surname>Chinetti</surname><given-names>G.</given-names></name><name><surname>Fruchart</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.</article-title>
<source>Nature</source>
<volume>393</volume>, <fpage>790</fpage>-<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1038/31701</pub-id><?supplied-pmid 9655393?><pub-id pub-id-type="pmid">9655393</pub-id></mixed-citation></ref><ref id="r53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabas-Madrid</surname><given-names>D.</given-names></name><name><surname>Nogales-Cadenas</surname><given-names>R.</given-names></name><name><surname>Pascual-Montano</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics.</article-title>
<source>Nucleic Acids Res</source>
<volume>40</volume>, <fpage>W478-483</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gks402</pub-id><?supplied-pmid 22573175?><pub-id pub-id-type="pmid">22573175</pub-id></mixed-citation></ref><ref id="r54"><mixed-citation publication-type="book">Team, R. D. C. (2011). R: A language and environment for statistical computing (Vienna, Austria, R Foundation for Statistical Computing).</mixed-citation></ref><ref id="r55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thun</surname><given-names>M. J.</given-names></name><name><surname>Henley</surname><given-names>S. J.</given-names></name><name><surname>Patrono</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <article-title>Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.</article-title>
<source>J Natl Cancer Inst</source>
<volume>94</volume>, <fpage>252</fpage>-<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/94.4.252</pub-id><?supplied-pmid 11854387?><pub-id pub-id-type="pmid">11854387</pub-id></mixed-citation></ref><ref id="r56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>E.</given-names></name><name><surname>Graves</surname><given-names>R. A.</given-names></name><name><surname>Budavari</surname><given-names>A. I.</given-names></name><name><surname>Spiegelman</surname><given-names>B. M.</given-names></name></person-group> (<year>1994</year><comment>a</comment>). <article-title>mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.</article-title>
<source>Genes Dev</source>
<volume>8</volume>, <fpage>1224</fpage>-<lpage>1234</lpage>. <pub-id pub-id-type="doi">10.1101/gad.8.10.1224</pub-id><?supplied-pmid 7926726?><pub-id pub-id-type="pmid">7926726</pub-id></mixed-citation></ref><ref id="r57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>E.</given-names></name><name><surname>Spiegelman</surname><given-names>B.</given-names></name></person-group> (<year>1994</year><comment>b</comment>). <article-title>Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.</article-title>
<source>Cell</source>
<volume>79</volume>, <fpage>1147</fpage>-<lpage>1156</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(94)90006-X</pub-id><?supplied-pmid 8001151?><pub-id pub-id-type="pmid">8001151</pub-id></mixed-citation></ref><ref id="r58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vane</surname><given-names>J. R.</given-names></name><name><surname>Bakhle</surname><given-names>Y. S.</given-names></name><name><surname>Botting</surname><given-names>R. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Cyclooxygenases 1 and 2.</article-title>
<source>Annual Review of Pharmacology and Toxicology</source>
<volume>38</volume>, <fpage>97</fpage>-<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.38.1.97</pub-id><?supplied-pmid 9597150?><pub-id pub-id-type="pmid">9597150</pub-id></mixed-citation></ref><ref id="r59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waku</surname><given-names>T.</given-names></name><name><surname>Shiraki</surname><given-names>T.</given-names></name><name><surname>Oyama</surname><given-names>T.</given-names></name><name><surname>Maebara</surname><given-names>K.</given-names></name><name><surname>Nakamori</surname><given-names>R.</given-names></name><name><surname>Morikawa</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>The nuclear receptor PPAR&#947; individually responds to serotonin- and fatty acid-metabolites.</article-title>
<source>EMBO J</source>
<volume>29</volume>, <fpage>3395</fpage>-<lpage>3407</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2010.197</pub-id><?supplied-pmid 20717101?><pub-id pub-id-type="pmid">20717101</pub-id></mixed-citation></ref><ref id="r60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>M.</given-names></name><name><surname>Hurteau</surname><given-names>G.</given-names></name><name><surname>Dessev</surname><given-names>C.</given-names></name><name><surname>Chan</surname><given-names>D.</given-names></name><name><surname>Geraci</surname><given-names>M. W.</given-names></name><name><surname>Winn</surname><given-names>R. A.</given-names></name><name><surname>Heasley</surname><given-names>L. E.</given-names></name><name><surname>Nemenoff</surname><given-names>R. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.</article-title>
<source>Mol Pharmacol</source>
<volume>62</volume>, <fpage>1207</fpage>-<lpage>1214</lpage>. <pub-id pub-id-type="doi">10.1124/mol.62.5.1207</pub-id><?supplied-pmid 12391285?><pub-id pub-id-type="pmid">12391285</pub-id></mixed-citation></ref><ref id="r61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Challenges in Drug Discovery for Thiazolidinedione Substitute.</article-title>
<source>Acta Pharmaceutica Sinica B</source>
<volume>1</volume>, <fpage>137</fpage>-<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2011.06.011</pub-id><?supplied-pmid 22427718?><pub-id pub-id-type="pmid">22427718</pub-id></mixed-citation></ref></ref-list></back></article>